SCHEMBL24315780

SCHEMBL24315780

O=C1Nc2cccc3c(C4(F)CN(Cc5ccccc5)C4)ccc1c23

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.41
GAA P10253 2/20 0.39
EPHX2 P34913 1/20 0.39
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 5/20 0.37
HSD17B10 Q99714 3/20 0.37
CASP1 P29466 2/20 0.37
CASP7 P55210 2/20 0.37
USP2 O75604 2/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
TYMS P04818 1/20 0.36
HPGD P15428 3/20 0.35
GLA P06280 1/20 0.35
ALPL P05186 1/20 0.35
POLB P06746 1/20 0.35
MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24316270 0.89 PARP1 (0.44) PARP1GAADRD2DRD4DRD3
SCHEMBL29611207 0.80 OPRL1 (0.48) PARP1GAADRD2DRD4DRD3
SCHEMBL24316271 0.80 OPRL1 (0.48) PARP1GAADRD2DRD4DRD3
SCHEMBL29611183 0.75 PARP1 (0.41) PARP1EPHX2DRD2DRD4DRD3
SCHEMBL24315947 0.75 PARP1 (0.41) PARP1EPHX2DRD2DRD4DRD3
SCHEMBL29073610 0.75 SIGMAR1 (0.39) DRD2KDM4E
SCHEMBL29610400 0.72 IKZF2 (0.46) ALDH1A1TSHR
SCHEMBL24315781 0.72 IKZF2 (0.46) ALDH1A1TSHR
SCHEMBL24315958 0.71 SIGMAR1 (0.40) PARP1DRD2KDM4EALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL6993686 0.67 MAOB (0.46) PARP1DRD2DRD4DRD3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 PARP1 1566/4885GAA 2982/4885EPHX2 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.